Crystal Induced Arthropathy

More documents

Recommendations

Info

Gout & Related Conditions Hypertension NHANES III – 69% w/ gout vs. 30% control Myocardial Infarction MRFIT –OR* 1.26 ( 1.14 –1.40) p < .001 Similar data from HPFS – fatal & non‐fatal Metabolic Syndrome NHANES III –63% vs 25% first gout attack precedes features of metabolic syndrome *OR – odds ratio
Gout & Related Conditions Obesity HPFS – prevalence of gout ↑ with ↑ BMI Type 2 Diabetes Mellitus MRFIT –RR of developing 1.34 (1.09‐1.64) NHANES III –OR 2.55 of having FBS > 110
Page 1 and 2: Update on Crystal Related Arthritis
Page 3 and 4: Gout A disorder related to monosod
Page 5 and 6: Gout ‐ Diagnosis Typically acute
Page 7 and 8: Compensated polarized microscopy -
Page 9: Gout in the Older Patient Incidenc
Page 16 and 17: Hyperuricemia - A Cause of or Marke
Page 18 and 19: So What Should We Do? Should we tr
Page 20 and 21: Gout - Treatment of Acute Attack C
Page 22 and 23: Gout ‐ Treatment Acute Attack AC
Page 24 and 25: Allopurinol Dose - Initial ‐ 10
Page 26 and 27: Allopurinol Hypersensitivity Syndro
Page 28 and 29: Febuxostat Approved in U.S. for 40
Page 30 and 31: Other Ways to Reduce Risk of Gout
Page 32 and 33: Treatments on the Horizon Acute at
Page 34 and 35: Calcium Pyrophosphate Dihydrate Dep
Page 36 and 37: Clincal Clues to Diagnosis Pseudog
Page 38 and 39: CPPD ‐ Diagnosis Other suggestiv
Page 40 and 41: From the ACR slide collection ©
Page 42: CPPD ‐ Treatment Psuedogout Asp

Crystal Induced Arthropathy

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?